Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $167.38M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 2.04M
Average 0.45M
Returns on capital
Inventiva S.A. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
1171.5%
avg 117.2%
ROIC
-64.2%
avg -288.9%
ROA
-136.7%
avg -64.5%
Analysis
ROE is currently the strongest return metric at 1171.5% versus its period average of 117.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Pierre Broqua | Co-Founder | EUR 462.63K | 64 | — | — |
Jean Volatier | Executive VP Finance & Corporate Social Responsibility | EUR 399.45K | 61 | — | — |
Jason A. Campagna | President of Research and Development & Chief Medical Officer | EUR 379.92K | 60 | — | — |
Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | EUR 253.99K | 57 | — | — |
Andrew Obenshain | Chief Executive Officer | EUR 171.03K | 52 | — | — |
Jennifer Nava | Chief Information Officer | — | — | — | — |
Pascaline Clerc | Executive Vice President of External and Corporate Affairs | — | 46 | — | — |
Susan Coles | Chief Legal Officer | — | 60 | — | — |
Christopher Benecchi | Chief Operating Officer | — | 54 | — | — |
Nazira Amra | Chief Commercial Strategy Officer | — | — | — | — |
Axel-Sven Malkomes | Chief Financial Officer | — | 59 | — | — |
Pamela Herbster | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -28.3% | +168.7% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -28.3% over three years. Forward estimates point to Revenue at +168.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Inventiva S.A. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IVA's management, answered from reported figures.
Who manages IVA?
Inventiva S.A. (IVA) lists 12 active executives. The top listed executive is Jason A. Campagna, President of Research and Development & Chief Medical Officer.
Continue the stock analysis
Jump to another research area for this company.